Engineered T cells secreting αB7-H3-αCD3 bispecific engagers (Mahidol University)

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameEngineered T cells secreting αB7-H3-αCD3 bispecific engagers (Mahidol University)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagersCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionAnti-CD3CD3 T-cell engagersAnti-CD276

TargetsT cell surface glycoprotein CD3CD276 antigen

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryThailand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMahidol University

China Registration ClassN/A

Develop Information

Active CompaniesMahidol University

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A